Claim 1: isolated an Antibody or Antigen binding fragment, comprising a variant of a variable domain of heavy chain (VH) pet1073g12 (sec. ID no. 1) that has not parat u00f3picos Waste and parat u00f3picos of TGFb and a light chain variable domain (VL) pet1073g12 (sec.ID no. 2) with parat u00f3picos Waste and not parat u00f3picos of TGFb.Where the VH Domain Includes up to 20 parat u00f3picos residue substitutions and substitutions of residues not until 20 parat u00f3picos； where VL Domain Includes up to 20 parat u00f3picos residue substitutions and substitutions of residues not until 20 parat u00f3picos； and where the said Antibody or Antigen binding fragment that is able to bind human (TGFB1 TGFb, tgfb2 and tgfb3).Claim 17: a Pharmaceutical composition comprising the Antibody or Antigen binding fragment thereof according to claim 1. Claim 21: an isolated Nucleic Acid encoding the Antibody or Antigen binding Fragment of claim 1. Claim 22: a Vector comprising the Nucleic Acid isolated from the claim 21.Claim 23: a host Cell comprising the Vector of claim 22.Claim 25: a method for treating a disease or condition that is directly or indirectly the activity of TGFb in a Human, which comprises administering a Pharmaceutical composition comprising a therapeutically effective amount of an Antibody or a fragment of a Union This nt u00edgeno of claim 1.Reivindicación 1: Un anticuerpo aislado, o fragmento de unión a antígeno de éste, que comprende una variante de un dominio de cadena pesada variable (VH) PET1073G12 (SEC. ID Nº 1) que tiene residuos paratópicos y no paratópicos de TGFb, y un dominio de cadena liviana variable (VL) PET1073G12 (SEC. ID Nº 2) que tiene residuos paratópicos y no paratópicos de TGFb, en donde el dominio VH comprende hasta 20 sustituciones de residuos paratópicos y hasta 20 sustituciones de residuos no paratópicos； en donde el dominio VL comprende hasta 20 sustituciones de residuos paratópicos y hasta 20 sustituciones de residuos no paratópicos； y en
